G-Nostics Ltd
G-Nostics hopes to give people suffering from nicotine addiction who wish to stop smoking, a powerful new tool, giving them greater control of their bodies than was previously possible.
Single nucleotide polymorphisms (SNPs) have been identified that have highly predictive associations with nicotine addiction and therefore tobacco consumption. These SNPs provide a method to help individuals decide which specific smoking cessation methods are most effective for them, offering personalised treatment to the 'smoker' which significantly increases their chances of quitting.
The invention has allowed the development of a simple diagnostic test to assess the degree of dependence and permits the allocation of specific treatment programmes to every individual attempting to quit.
Contact
Mr Mark Tucker, CEO
E tuc_ker@msn.com